Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tarah Wafzig

Nurse Practitioner Shepherdsville, KY Nurse Practitioner

NPI 1124420237 CMS profile 11176782

187 Adam Shepherd Pkwy Ste 5, Shepherdsville, KY 40165

Open in the dashboard

General payments

$11,325

808 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tarah Wafzig of Shepherdsville, KY is reported in the CMS Open Payments database as having received $11,325 across 808 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,843 184
2024 General $2,578 177
2023 General $1,964 152
2022 General $2,103 171
2021 General $1,838 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tarah Wafzig
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tarah Wafzig were reported at $2,843. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tarah Wafzig Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,838 $135 $40–$426 $132
2022 $2,103 $152 $48–$470 $149
2023 $1,964 $166 $54–$529 $160
2024 $2,578 $173 $55–$556 $164
2025 $2,843 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,707 137 payments
  2. Novo Nordisk Inc $1,238 101 payments
  3. Amgen Inc. $1,164 100 payments
  4. Pfizer Inc. $1,125 98 payments
  5. Lilly USA, LLC $667 56 payments
  6. AstraZeneca Pharmaceuticals LP $658 22 payments
  7. Novartis Pharmaceuticals Corporation $406 24 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $405 26 payments
  9. Esperion Therapeutics, Inc. $405 27 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $391 24 payments
  11. Other $3,160 193 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,305 807 payments
  2. Long term medical supply or device loan $20 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $743 51 payments
  2. QULIPTA $699 52 payments
  3. NURTEC ODT Pain $654 70 payments
  4. Ozempic $597 51 payments
  5. RYBELSUS $597 51 payments
  6. Otezla $568 61 payments
  7. FARXIGA $567 15 payments
  8. NURTEC ODT Primary Care $536 45 payments
  9. VRAYLAR $501 51 payments
  10. Repatha $492 50 payments
  11. Other $10,349 651 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

2,845

Median for Nurse Practitioner: 389

Drug cost

$495,742

Median for Nurse Practitioner: $21,885

Branded share of claims

25.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 77 $122,885
Farxiga Dapagliflozin Propanediol Brand 53 $66,259
Ozempic Semaglutide Brand 27 $47,373
Jardiance Empagliflozin Brand 38 $46,235
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 40 $46,103
Kerendia Finerenone Brand 30 $35,561
Vascepa Icosapent Ethyl Brand 30 $27,604
Repatha Sureclick Evolocumab Brand 20 $19,870
Januvia Sitagliptin Phosphate Brand 20 $19,161
Eliquis Apixaban Brand 13 $15,587

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$40,584

Of which drugs: $13,301

Medicare patients

103

Average age 71

Services billed

843

70 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 36%
Diabetes 25%
Osteoporosis 23%
Ischemic heart disease 19%
COPD 17%
Atrial fibrillation 14%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 22 22 $6,398
Sarscv2 vac 30mcg trs-suc im 91320 Office 12 13 $1,792
Vaccine for influenza for injection into muscle 90653 Office 21 21 $1,718

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $195
$195 — —
UBRELVY
  • AbbVie, Inc. $166
$166 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $164
$164 — —
Repatha
  • Amgen Inc. $144
$144 20 —
NURTEC ODT
  • PFIZER INC. $138
$138 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

808 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record